Juvenile Myoclonic Epilepsy - an experience from north western India

Panagariya, A.; Sureka, R. K.; Sardana, V.

doi:10.1034/j.1600-0404.2001.00293.x

Cited by 7 publications

(10 citation statements)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The open series that have been published using VPA show a 41–88% seizure‐free rate for patients receiving VPA, either as an add‐on medication or as monotherapy (20, 21). Case studies have also shown that a low, once‐daily dose (500 mg) of VPA can effectively control JME and keep patients seizure free for as long as 2 years (22, 23).…”

Section: Clinical Trials In Various Idiopathic Generalized Epilepsiesmentioning

confidence: 99%

Chronic Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsy

Bourgeois

2003

Epilepsia

View full text Add to dashboard Cite

Summary:As a group, idiopathic generalized epilepsies (IGEs) have the highest rates of complete seizure control with medication. However, there are little evidence-based data to guide drug choice for treatment. Examples of IGE include absence epilepsy, generalized tonic-clonic epilepsy, and juvenile myoclonic epilepsy. Generalized epilepsies seem to be particularly vulnerable to seizure aggravation, and medications that are primarily effective against partial seizures are more commonly involved in seizure aggravation than other medications. A review of current research has shown that only a few medications can control IGE without potentially causing seizure aggravation. Broad-spectrum antiepileptic drugs such as valproate (VPA), lamotrigine, and topiramate are extremely effective at controlling a variety of seizures without causing excessive seizure aggravation. Among these drugs, VPA has the longest clinical experience history and the largest body of published data.

show abstract

Section: Clinical Trials In Various Idiopathic Generalized Epilepsiesmentioning

confidence: 99%

Chronic Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsy

Bourgeois

2003

Epilepsia

View full text Add to dashboard Cite

show abstract

“…The open series that have been published using VPA show a 41%–88% seizure-free rate for patients receiving VPA, either as an add-on medication or as monotherapy (Atakli et al 1998; Kleveland and Engelsen 1998). Case studies have also shown that a low, once-daily dose (500 mg) of VPA can effectively control JME and keep patients seizure free for as long as 2-years (Panagariya et al 2001; Karlovassitou-Koriari et al 2002). Newer studies that examined the efficacy of lamotrigine, topiramate and valproate in JME have all shown that valproate has the best efficacy of the three (Prasad et al 2003; Nicolson et al 2004; Mohanraj and Brodie 2005).…”

Section: Treatmentmentioning

confidence: 99%

Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy

Auvin¹

2008

NDT

View full text Add to dashboard Cite

Drug treatment of Juvenile myoclonic epilepsy (JME) is mainly based on clinical experience and prospective and retrospective studies, with little evidence from randomized clinical trials. There are no head-to-head comparisons between old and new antiepileptic drugs (AEDs) and no drugs licensed specifically for JME. Valproate is unquestionably the drug of the first choice in men with JME. In women, lamotrigine should be preferred regarding teratogenicity and side effects of valproate. In addition, levetiracetam and topiramate are effective and can be use in combination or as second line treatment. Some AEDs can aggravate JME. In addition of AEDs, non-pharmacological treatments are important in JME. JME usually require lifelong treatment because seizures nearly always return after withdrawal of therapy.

show abstract

“…The open series that have been published using VPA show a 41–88% seizure‐free rate for patients receiving VPA, either as an add‐on medication or as monotherapy [6,29]. Case studies have also shown that a low, once‐daily dose (500 mg) of VPA can effectively control JME and keep patients seizure free for as long as 2 years [30,31]. Newer studies that examined the efficacy of LTG, TPM, and VPA in JME have all shown that VPA has the best efficacy of the three [32–35].…”

Section: Treatmentmentioning

confidence: 99%

Treatment of Juvenile Myoclonic Epilepsy

Auvin¹

2008

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

Drug treatment of juvenile myoclonic epilepsy (JME) is mainly based on clinical experience and prospective and retrospective studies, with little evidence from randomized clinical trials. There are almost no head-to-head comparisons between old and new antiepileptic drugs (AEDs). Valproate is the drug of the first choice in men with JME. In women, lamotrigine (LTG) should be preferred regarding teratogenicity and side effects of valproate. Levetiracetam (LEV) is also effective. Recent data suggest that it may soon be used as first line treatment. Some AEDs can aggravate JME. In addition to AEDs, nonpharmacological treatments are important in JME. JME usually requires lifelong treatment because seizures nearly always return after withdrawal of therapy.

show abstract

Juvenile Myoclonic Epilepsy - an experience from north western India

Abstract: The majority of JME patients responded well not only to sodium valproate in dosages lower than usually prescribed but required very small dosages for maintenance after a seizure free period of 2 years.

Cited by 7 publications

References 16 publications

Chronic Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsy

Chronic Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsy

Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy

Treatment of Juvenile Myoclonic Epilepsy

Contact Info

Product

Resources

About